| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: =99.81%
| Targets |
DHMC does not have a single defined molecular target but exerts its effects through its antioxidant properties. Its mechanism of action is primarily attributed to its ability to scavenge free radicals, which helps protect cells from oxidative damage. The compound's structure, featuring two hydroxyl groups on the coumarin ring, is key to its radical scavenging activity. It also demonstrates potent and specific anti-proliferation and apoptosis-inducing effects on several tumor cell lines, suggesting additional mechanisms of action beyond antioxidant activity.
|
|---|---|
| ln Vitro |
In vitro, DHMC exhibits excellent radical scavenging properties, which have been characterized in various biochemical assays. It has been shown to have potent and specific anti-proliferation and apoptosis-inducing effects on several tumor cell lines. The compound also demonstrates strong inhibitory activity against membrane lipid peroxidation. These properties make DHMC a valuable tool for studying oxidative stress and its role in cancer and other diseases.
|
| ln Vivo |
In vivo, DHMC's antioxidant and anti-proliferative properties suggest potential therapeutic applications. However, detailed in vivo studies are limited. The compound is primarily used as a precursor in the synthesis of 4-methylcoumarin derivatives, which may have various biological activities. Its radical scavenging properties make it a candidate for further in vivo studies in models of oxidative stress-related diseases.
|
| Enzyme Assay |
In vitro assays for DHMC typically involve measuring its radical scavenging activity using standard methods such as the DPPH (2,2-diphenyl-1-picrylhydrazyl) assay or the ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) assay. The compound's ability to inhibit lipid peroxidation is also assessed. These assays are used to quantify the compound's antioxidant potency and to compare it with other known antioxidants.
|
| Cell Assay |
Cell-based assays for DHMC involve treating various cell lines with the compound and measuring its effects on cell proliferation, apoptosis, and oxidative stress. Tumor cell lines are commonly used to study its anti-proliferative and apoptosis-inducing effects. Cells are treated with varying concentrations of DHMC, and endpoints such as cell viability, caspase activation, and reactive oxygen species (ROS) levels are measured. These studies help elucidate the compound's mechanism of action and its potential as an anticancer agent.
|
| Animal Protocol |
In vivo animal studies for DHMC are limited. The compound is primarily used as a research tool in vitro. However, its radical scavenging properties and anti-proliferative effects suggest potential for in vivo studies in models of cancer and oxidative stress-related diseases. Further research is needed to explore its pharmacokinetics and efficacy in animal models.
|
| ADME/Pharmacokinetics |
DHMC has a molecular weight of 192.17 g/mol and a molecular formula of C10H8O4. It is soluble in DMSO at 38 mg/mL (197.74 mM). For in vivo administration, it can be prepared as a homogeneous suspension in CMC-NA at ≥5 mg/mL. For storage, the powder should be kept at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
The toxicological profile of DHMC has not been extensively characterized. As a research compound, it should be handled with appropriate safety precautions. Its use is limited to research applications.
|
| References |
|
| Additional Infomation |
7,8-Dihydroxy-4-methyl-1-benzopyran-2-one is a hydroxycoumarin.
DHMC is a research compound with no approved human therapeutic use. It is primarily used as a precursor in the synthesis of 4-methylcoumarin derivatives, which have various biological activities. Its excellent radical scavenging properties make it a valuable tool for studying oxidative stress and antioxidant mechanisms. The compound's anti-proliferative and apoptosis-inducing effects on tumor cell lines also make it a subject of interest in cancer research. |
| Molecular Formula |
C10H8O4
|
|---|---|
| Molecular Weight |
192.1681
|
| Exact Mass |
192.042
|
| CAS # |
2107-77-9
|
| PubChem CID |
5355836
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
421.5±45.0 °C at 760 mmHg
|
| Melting Point |
242-246 °C(lit.)
|
| Flash Point |
176.0±22.2 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.652
|
| LogP |
1.95
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
14
|
| Complexity |
284
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NWQBYMPNIJXFNQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H8O4/c1-5-4-8(12)14-10-6(5)2-3-7(11)9(10)13/h2-4,11,13H,1H3
|
| Chemical Name |
7,8-dihydroxy-4-methylchromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~433.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2037 mL | 26.0186 mL | 52.0373 mL | |
| 5 mM | 1.0407 mL | 5.2037 mL | 10.4075 mL | |
| 10 mM | 0.5204 mL | 2.6019 mL | 5.2037 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA